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ABSTRACT
Introduction Metformin can accumulate and cause lactic 
acidosis in patients with renal insufficiency. Metformin is 
known to inhibit mitochondria, while renal secretion of 
the drug by proximal tubules indirectly requires energy. 
We investigated whether addition of metformin before or 
during ex vivo isolated normothermic machine perfusion 
(NMP) of porcine and rat kidneys affects its elimination.
Research design and methods First, Lewis rats were 
pretreated with metformin or saline the day before 
nephrectomy. Subsequently, NMP of the kidney was 
performed for 90 min. Metformin was added to the 
perfusion fluid in one of three different concentrations 
(none, 30 mg/L or 300 mg/L). Second, metformin was 
added in increasing doses to the perfusion fluid during 4 
hours of NMP of porcine kidneys. Metformin concentration 
was determined in the perfusion fluid and urine by liquid 
chromatography- tandem mass spectrometry.
Results Metformin clearance was approximately 4–5 
times higher than creatinine clearance in both models, 
underscoring secretion of the drug. Metformin clearance 
at the end of NMP in rat kidneys perfused with 30 mg/L 
was lower than in metformin pretreated rats without the 
addition of metformin during perfusion (both p≤0.05), but 
kidneys perfused with 300 mg/L trended toward lower 
metformin clearance (p=0.06). Creatinine clearance was 
not different between treatment groups. During NMP of 
porcine kidneys, metformin clearance peaked at 90 min 
of NMP (18.2±13.7 mL/min/100 g). Thereafter, metformin 
clearance declined, while creatinine clearance remained 
stable. This observation can be explained by saturation of 
metformin transporters with a Michaelis- Menten constant 
(95% CI) of 23.0 (10.0 to 52.3) mg/L.
Conclusions Metformin was secreted during NMP of both 
rat and porcine kidneys. Excretion of metformin decreased 
under increasing concentrations of metformin, which 
might be explained by saturation of metformin transporters 
rather than a self- inhibitory effect. It remains unknown 
whether a self- inhibitory effect contributes to metformin 
accumulation in humans with longer exposure times.
INTRODUCTION
The biguanide metformin is widely used as an 
antihyperglycemic agent to treat patients with 
type 2 diabetes. Although the exact mech-
anism of action is unknown, it is generally 
presumed that mild inhibition of complex I 
within the mitochondrial electron transport 
underlies most of the pleiotropic effects of 
metformin.1 The primary mode of elimi-
nation is excretion of the unchanged drug 
in urine.2 In some patients with acute renal 
insufficiency, metformin can accumulate and 
cause lactic acidosis. The reported incidence 
of metformin- associated lactic acidosis ranges 
from 3 to 10 per 100 000 patient- years and 
Significance of this study
What is already known about this subject?
 ► Metformin can accumulate and cause lactic acidosis 
in patients with renal insufficiency, which is a severe 
complication of metformin therapy.
 ► Metformin is known to inhibit mitochondria, while 
renal secretion of the drug by proximal tubules indi-
rectly requires energy and might be saturated.
What are the new findings?
 ► Metformin was secreted during normothermic ma-
chine perfusion of both rat and porcine kidneys.
 ► Metformin clearance was reduced under increasing 
concentrations of the drug, indicating saturation of 
transporters affecting its elimination.
 ► There is no indication that other tubular functions 
were altered when exposed to concentrations of 
metformin considered to be toxic in vivo.
How might these results change the focus of 
research or clinical practice?
 ► Further research is needed to elucidate the under-
lying mechanism how metformin- induced lactic ac-
idosis develops.
 ► Is metformin secretion concentration- dependently 
reduced in patients using metformin?
 ► Does the severity of chronic kidney disease affect 
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is associated with a high mortality rate. However, the 
full clinical context or metformin blood concentration 
is often not reported, making it difficult to distinguish 
metformin- associated from metformin- induced lactic 
acidosis, respectively.3 Because of the risk to develop 
metformin- associated lactic acidosis (defined as lactate 
≥5 mmol/L, pH <7.35 and metformin concentration 
>5 mg/L),3 metformin is currently contraindicated in 
patients with severe chronic kidney disease.4 Moreover, 
it is recommended to be used with caution when condi-
tions are present that may reduce renal function,4 which 
in clinical practice leads to discontinuation of metformin 
48 hours before surgery or coronary angiography.5 6
Renal clearance of metformin is approximately four 
times higher than the glomerular filtration rate, indi-
cating secretion of the drug.2 In the proximal tubules, 
metformin is primarily taken up by organic cation trans-
porter (OCT)-2 through facilitated transport down an 
electrochemical gradient.7 Subsequently, metformin is 
luminally excreted by OCT-1 and multidrug and toxin 
extrusion transporter (MATE)-1 and MATE-2.2 The 
latter are secondary active transporters with an ion- 
coupled substrate.7 Although indirect, the mediation 
of transcellular movement against gradients requires 
ATP.7 Abundant mitochondria in the epithelial cells of 
the proximal tubule, estimated as 30%–40% of the total 
volume, support the extraordinarily high energy demand 
of these cells.8 In times that MATE transporters were 
not yet characterized,9 accumulation of cimetidine in 
canine kidney cortex slices and of tetraethylammonium 
in rat kidney slices, respectively, was hampered when 
exposed to hypoxia or potassium cyanide, underscoring 
that organic cation transport in general is an energy- 
dependent process.10 11 However, it is unknown to which 
extent metformin transport specifically is influenced by 
changes in cellular energy.
Combining the paradigms that mitochondria in the 
proximal tubules facilitate transport with mild inhibition 
of mitochondria by metformin, we investigated whether 
the addition of metformin to two ex vivo isolated normo-
thermic machine perfusion (NMP) rat and porcine 
kidney models affects the excretion of the drug.
RESEARCH DESIGN AND METHODS
Rat kidney study
Animals
Male Lewis rats (weighing 270–300 g) were obtained 
from Harlan Laboratories (Boxmeer, The Netherlands). 
Animals received care according to the Dutch Law on 
Animal Experiments and had ad libitum access to food 
and water.
Experimental design
Rats were treated with 300 mg/kg body weight metformin 
(1,1- dimethylbiguanide hydrochloride, Sigma- Aldrich, St. 
Louis, Missouri, USA) dissolved in saline or saline alone 
via oral gavage at 12 and 2 hours before nephrectomy. 
In previous experiments, this dose resulted in metformin 
concentrations comparable to those found in humans 
during maintenance metformin therapy.12 After nephrec-
tomy, experimental kidneys were preserved by static cold 
storage for 24 hours, while the contralateral (ie, non- 
perfused) kidney was stored in some cases at −80°C for 
further analysis. Experimental kidneys were subsequently 
perfused for 90 min in an ex vivo NMP setup with the 
addition of no metformin, 30 mg/L metformin or 300 
mg/L metformin. The latter metformin concentration 
was chosen to examine its effect on active transport 
processes, but should be considered to be massive as this 
concentration was only reported in an exceptional case 
of excessive metformin ingestion.13 The rat study had 
thus five metformin groups and one control group, all 
consisting of five to six kidneys (figure 1A).
Organ retrieval and preservation
Rats were anesthetized with 2%–5% isoflurane, and lapa-
rotomy was done via a midline incision. After antico-
agulation with 250 IU heparin (Leo Pharma, Bellerup, 
Denmark), cardiac arrest was achieved by inducing a 
heart tamponade manually by external compression. 
After 15 min of warm ischemia time, nephrectomy of the 
left kidney was performed. The renal artery and ureter 
were cannulated. The renal vein was not cannulated. The 
kidney was flushed in situ with 10 mL saline and 5 mL 4°C 
Belzer University of Wisconsin (UW) Cold Storage Solu-
tion (Bridge to Life, Columbia, South Carolina, USA). 
Once removed, kidneys were flushed again with cold UW 
and stored in UW at 4°C for 24 hours.
Normothermic machine perfusion
The rat NMP methods were described previously.14 
Briefly, a pressure- controlled NMP was performed using 
a roller pump (Ismatec ISM404, Zürich, Switzerland). 
The pressure was set at 102 mm Hg and measured at 
the renal artery using a pressure sensor (Edwards Life-
sciences, Irvine, California, USA). The perfusion fluid 
consisted of 100 mL William’s Medium E supplemented 
with 30 mmol/L HEPES, 50 g/L albumin, and 7 mmol/L 
creatinine (all Sigma- Aldrich, St. Louis). According to 
the experimental treatment group, no metformin, 30 
mg/L metformin or 300 mg/L metformin was added to 
the perfusion fluid at the start of NMP. Perfusion fluid 
was oxygenated with 95% oxygen and 5% carbon dioxide 
(carbogen) with a flow of 0.5 L/min. The temperature of 
the perfusion fluid was maintained stably at 37°C using 




Kidneys from female Dutch Landrace pigs were collected 
from a commercial abattoir after the animals were 
stunned and exsanguinated according to standard proce-
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in a beaker containing 25 000 IU of unfractionated 
heparin (Leo Pharma).
Experimental design
The experimental group consisted of seven kidneys, in 
which 2 mg metformin (4 mg/L) was added at the start 
of 3 hours of hypothermic machine perfusion (HMP). 
Before the start of NMP, 3.3 mg (4 mg/L) metformin 
was added to the perfusion fluid. Subsequently during 
NMP, the infusion speed of an infusion pump containing 
metformin dissolved in Ringer’s lactate solution (in a 
concentration of 20 mg/mL) was increased every half 
hour according to a prespecified schedule presented in 
online supplementary table 2. This schedule was based on 
human pharmacokinetic data indicating that metformin 
clearance is four times higher than the creatinine clear-
ance.2 In the control group, six kidneys were perfused 
without addition of metformin (figure 1A).
Organ retrieval and preservation
After 30 min of warm ischemia time, the kidney was flushed 
with 180 mL cold saline. Subsequently, the kidney was 
preserved with oxygenated HMP (<7°C) using a commer-
cially available pulsatile pressure- controlled pump system 
(Kidney Assist Transport, Organ Assist, Groningen, The 
Netherlands) for 3 hours. The kidneys were perfused 
with 500 mL UW machine perfusion solution (Belzers 
MP, Bridge to Life), supplemented with 2 mg metformin 
in the experimental group. The mean arterial pressure 
was set at 25 mm Hg. With a fixed flow of 100 mL/min, 
100% oxygen was supplied to the oxygenator (Hilite LT 
1000, Medos Medizintechnik, Stolberg, Germany).
Normothermic machine perfusion
A disposable perfusion circuit similar to that of HMP was 
used during NMP.15 Four hours of NMP was performed 
with 500 mL leukocyte depleted (BioR 02 plus, Fresenius 
Kabi, Bad Homburg, Germany) autologous oxygenated 
(carbogen, flow 0.5 L/min) blood diluted with 300 mL 
Ringer’s lactate solution, 10 mL glucose 5% (both Baxter, 
Utrecht, The Netherlands) and 10 mL sodium bicar-
bonate 8.4% (B. Braun, Melsungen, Germany). Before 
the start of NMP, the perfusion fluid was primed with 
1000/200 mg amoxicillin- clavulanate (Sandoz, Almere, 
The Netherlands), 6 mg dexamethasone (B. Braun), 90 
mg creatinine, 6 mg mannitol and 2 mg sodium nitro-
prusside (all Sigma- Aldrich; online supplementary table 
1). In the experimental group, 3.3 mg metformin was 
added to the perfusion fluid before the start of NMP. 
During NMP, metformin was infused in the experimental 
group using an Alaris syringe pump (BD, Wokingham 
Berkshire, UK) controlled by a custom- made Android 
application to infuse according to a predefined schedule 
(online supplementary table 2). During NMP, in both 
groups a nutrient mixture was infused including amino 
acids, glucose, insulin and sodium bicarbonate (online 
supplementary table 1). Of the compounds added before 
and during NMP, nitroprusside was given as vasodilator 
to increase renal blood flow,16 mannitol was given to 
decrease cellular swelling,17 while leukocytes were filtered 
out of the blood and dexamethasone was administered, 
respectively, to decrease the inflammatory response.18 
These compounds are proposed as preservation strategy 
surrounding kidney transplantation to reduce ischemia- 
reperfusion injury,19 and have been deemed necessary to 
Figure 1 (A) Schematic representation of the experimental groups in the rat and porcine kidney study, respectively. Oral 
pretreatment of rats via oral gavage occurred twice the day before nephrectomy. Rat kidneys were preserved for 24 hours with 
static cold storage, while 3 hours of hypothermic machine perfusion (HMP) was performed for porcine kidneys. Normothermic 
machine perfusion in rat kidneys lasted 90 min, whereas porcine kidneys were perfused for 240 min. (B) Metformin 
concentration measured using liquid chromatography tandem- mass spectrometry in the perfusate during normothermic 
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support perfusion and renal function when establishing 
our NMP model (non- published data).
The system measured pressure just before the renal 
artery (Edwards Lifesciences) and was set to achieve a 
mean arterial pressure of 80 mm Hg. The arterial flow 
was recorded using an ultrasonic clamp- on flow probe 
(ME7PXL, Transonic Systems, Ithaca, New York, USA). 
The renal vein was not cannulated. Urine was collected 
and was replaced with a corresponding volume of Ringer’s 
lactate solution (Baxter). The temperature of the perfu-
sion fluid was maintained at 37°C using an integrated 
heat exchanger of the oxygenator that was connected to 
a water bath (Julabo). The insulated perfusion box was 
heated using a radiator/ventilator combination (Tristar 
Europe, Tilburg, The Netherlands).
Laboratory analysis
Perfusion fluid and urine samples collected during NMP 
were centrifuged (1300 g for 10 min in the rat model 
and 1000 g for 12 min in the porcine model, respectively, 
both at 4°C) and the supernatant was stored at −80°C 
for future analysis. After perfusion, cortical kidney tissue 
was immediately frozen in liquid nitrogen. Only during 
the last 30 min of NMP in the rat kidney study, sufficient 
urine was collected to determine metformin clearance. 
Because only three urine samples per pretreatment 
group of kidneys perfused with 300 mg/L metformin 
were available, both pretreatment groups were combined 
for statistical analyses.
Metformin concentration analysis
Metformin concentration was determined in whole 
blood, plasma, urine, and kidney tissue by liquid 
chromatography- tandem mass spectrometry (LC- MS/
MS). In order to determine the metformin concentra-
tion in tissue, frozen cortical kidney tissue was crushed 
at liquid nitrogen temperature using a mortar and pestle 
to a fine powder. After a single freeze- thaw cycle, the 
mass approximated the consistency of whole blood and 
was deemed adequately homogenized to determine the 
metformin concentration. For all specimens, a volume 
of 10 µL sample was mixed with 750 µL precipitation 
reagent, consisting of a mixture of methanol and aceto-
nitrile (4:21, vol/vol) and 2H6- metformin 0.1 mg/L (J.H. 
Ritmeester, Nieuwegein, The Netherlands). The samples 
were then centrifuged at 10 000 g for 5 min, and 5 µL 
of the supernatant was injected on the LC- MS/MS. The 
analysis was performed on a triple- stage quadrupole 
Quantum Access Max mass spectrometer coupled with 
a Vanquish ultra- performance liquid chromatography 
pump, a Vanquish autosampler and a Vanquish column 
oven (Thermo Scientific, San Jose, California, USA). Vali-
dation of the bioanalyses was performed according to the 
guidelines of the European Medicine Agency regarding 
validation of a bioanalysis method.20
Determination of creatinine and sodium in plasma and 
urine was performed by the clinical chemistry laboratory 
of the University Medical Center Groningen according 
to standard biochemical methods. Creatinine clearance, 
metformin clearance and fractional sodium excretion 
were calculated to estimate glomerular filtration rate, 
metformin excretion and tubular function, respectively 
(table 1). Clearance was calculated by dividing the 
elimination rate in urine from the previous timepoint 
at which urine was collected to the current timepoint 
by the current perfusion fluid concentration (table 1). 
Metformin- to- creatinine clearance ratio was calculated 
Table 1 Equations to calculate different parameters
Parameter (unit) Equation
Clearance at, eg, 90 min after NMP
(mL/min)  
Urine productiont60→t90·urine concentrationt90
Perfusion fluid concentrationt90  
Creatinine clearance (mL/min/100 g)
 
Urine creatinine[μmol/L]·urine production [mL/min]
Perfusion fluid creatinine [μmol/L]
Kidney weight [100g]  
Metformin clearance (mL/min/100 g)
 
Urine metformin [mg/L]·urine production [mL/min]
Perfusion fluid metformin [mg/L]
Kidney weight [100g]  
Metformin- to- creatinine clearance ratio
 
Metformin clearance [mL/min/100 g]
Creatinine clearance [mL/min/100 g] 
Fractional sodium excretion (%)
 100 ·
Urine sodium [mmol/L]·perfusion fluid creatinine [μmol/L]
Perfusion fluid sodium [mmol/L]·urine creatinine [μmol/L]  
Oxygen consumption (mLO2/min/100 g)
 
Flow [L/min]·(arterial oxygen content [mLO2/L]−venous oxygen content [mLO2/L])
Kidney weight[100g]  



























Units of the parameters used within the equations are depicted with hard brackets to avoid confusion with regular brackets. In the porcine 
study, a total oxygen binding capacity of hemoglobin of 24.8 mLO2/mmol and 0.225 mLO2/kPa oxygen solubility in water at 37°C was 
assumed.
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to determine the proportion of metformin that is elim-
inated more than creatinine, indicating secretion of the 
drug when assuming negligible creatinine secretion.
Renal metabolic markers
Oxygen consumption was calculated based on the differ-
ence between the arterial and venous oxygen content 
(table 1).18 The total oxygen content in the rat kidney 
study was measured directly in the arterial and venous 
perfusion fluid (PreSens, Regensburg, Germany). In the 
porcine kidney study, arterial and venous samples were 
analyzed using an ABL800 blood gas analyzer (Radi-
ometer, Brønhøj, Denmark). Subsequently, the oxygen 
content of the perfusion fluid was calculated by adding 
the free dissolved oxygen fraction to the hemoglobin 
bound oxygen fraction. We assumed a total oxygen 
binding capacity of hemoglobin of 24.8 mLO2/mmol 
and 0.225 mLO2/kPa oxygen solubility in water at 37°C 
(table 1).
Glucose and lactate levels in the rat study were 
measured using the same blood gas analyzer. Lactate 
production and glucose consumption throughout the 
rat kidney experiment were calculated by subtracting 
the lactate or glucose level at the start of NMP from the 
level at the end of the experiment. The addition of Ring-
er’s lactate to the perfusion fluid influenced our ability 
to determine lactate production in the porcine kidney 
study accurately. As an indicator of the energetic state of 
the kidney, ATP content was determined according to 
previously reported methods in porcine cortical tissue 
obtained at the end of NMP.21
Real-time quantitative PCR
Total RNA was extracted from kidney sections using 
TRIzol (Life Technologies, Gaithersburg, Maryland, 
USA). Samples were verified for the absence of genomic 
DNA contamination by performing real- time PCR reac-
tions in which the addition of reverse transcriptase was 
omitted, using β-actin primers. For complementary DNA 
(cDNA) synthesis, 1 µL T11VN Oligo- dT (0.5 µg/µL) 
and 1 µg messenger RNA (mRNA) were incubated for 10 
min at 70°C and subsequently cooled. cDNA was synthe-
sized by adding a mixture containing 0.5 µL RNase water 
(Promega, Madison, Wisconsin, USA), 0.5 µL RnaseOUT 
Ribonuclease inhibitor, 4 µL 5 times first strand buffer, 
2 µL dithiothreitol, 1 µL deoxyribonucleotide triphos-
phate and 1 µL M- MLV reverse transcriptase (all Invit-
rogen, Carlsbad, California, USA). The mixture was kept 
at 37°C for 50 min. Subsequently, reverse transcriptase 
was inactivated by incubating the mixture for 15 min at 
70°C. Amplification of several gene fragments involved 
in renal tubular transport was done with the primer 
sets outlined in online supplementary table 3. cDNA 
obtained from rats was used to test primer efficiency 
and as an internal reference during PCR. Gene expres-
sion was normalized with the mean of β-actin mRNA 
content. PCR was carried out on the TaqMan 7900HT 
Real- Time PCR system (Applied Biosystems, Waltham, 
Massachusetts, USA), according to procedures outlined 
earlier.22 The 2-ΔΔCt method was used to calculate the 
expression mRNA levels, where the Ct value represents 
the difference between cycle threshold values.
Statistical analysis
All data are expressed as mean±SEM. When comparing 
two groups at a single time point, differences were assessed 
using an unpaired Student’s t- test and, in case of more 
than two independent groups, using analysis of variance 
(ANOVA). To determine the total oxygen consumption, 
the area under the curve was approximated by dividing 
the curve into segments of 15 min, calculating the area 
of the trapezoids under these segments using Excel 2010 
(Microsoft, Redmond, Washington, USA). Analyses were 
performed using SPSS Statistics V.23 (IBM, Armonk, New 
York, USA). A centered fifth- order polynomial model 
was used to fit the cross- sectional relation of metformin 
perfusate concentration with the urinary elimination 
rate (online supplementary figure 1a). Based on these 
results, non- linear pharmacokinetics using a Michaelis- 
Menten model were assessed and the corresponding 
Michaelis- Menten constant (Km) with 95% CI was calcu-
lated in Prism V.8.0.1 (GraphPad Software, San Diego, 
California, USA).
A linear mixed- effects repeated measures model with 
random slope and intercept was used to analyze the 
impact of the treatment (metformin or control) on frac-
tional sodium excretion, oxygen consumption and pH 
over time. Fixed effects were time, treatment group and 
the interaction of treatment group with time. Among 
metformin- treated porcine kidneys, a similar analysis 
was performed using type of clearance (metformin or 
creatinine) instead of treatment group as fixed effect. 
Individual kidneys were considered as random effect. 
The covariance matrix of residuals used in all models was 
unstructured. A restricted maximum likelihood approach 
was used. Modeling was performed using Stata V.14.2 
(StataCorp, College Station, Texas, USA). All statistical 
tests are two- tailed, and a p≤0.05 was considered to be 
statistically significant.
RESULTS
Metformin perfusion fluid concentration
Metformin perfusion fluid concentrations in the rat 
kidney study were adequately achieved for each treat-
ment group (figure 1B). Rats pretreated with metformin 
whose kidneys were subsequently perfused without 
the addition of metformin yielded a perfusion fluid 
metformin concentration of 2.8±2.6 mg/L at the start 
of NMP. Oral metformin or saline pretreatment of rats 
did not affect metformin perfusion fluid concentration 
at the start of NMP in the 30 mg/L group (22.4±0.1 
(metformin pretreated) vs 23.0±0.5 (saline pretreated) 
mg/L, p=0.39) or in the 300 mg/L group (268.8±7.4 
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For the first 90 min during NMP in the porcine kidney 
study, metformin perfusion fluid concentration remained 
stable with a maximum of 5.1±1.2 mg/L (figure 1C). After 
that, metformin perfusion fluid concentration increased 
rapidly until a concentration of 179.3±38.8 mg/L was 
reached at the end of the experiment. No significant 
differences were found when comparing metformin 
concentrations measured in whole blood and plasma 
(online supplementary figure 2).
Metformin clearance
Metformin clearance during the last 30 min of NMP in 
rat kidneys only pretreated with metformin was 2.7±0.4 
times higher than creatinine clearance (figure 2A–C). 
Compared with rats that were pretreated with metformin 
and whose kidneys subsequently were perfused without 
the addition of metformin, metformin excretion in 
kidneys perfused with 30 mg/L metformin was decreased, 
irrespective of metformin pretreatment. Metformin 
clearance and the metformin- to- creatinine clearance 
ratio was even further decreased in kidneys perfused 
with 300 mg/L metformin, as compared with metformin 
pretreated rats that were subsequently perfused without 
addition of metformin, and when compared with kidneys 
perfused with 30 mg/L metformin when both pretreat-
ment groups were combined (figure 2A–C). Of note, 
creatinine clearance did not differ during the last 30 min 
of NMP in the rat study (figure 2B). Non- linear curve 
fitting of the relation of metformin perfusate concen-
tration with urinary elimination rate was uninformative 
because of its experimental design (online supplemen-
tary figure 1b).
During NMP of porcine kidneys, overall metformin 
clearance was higher than the creatinine clearance 
(Pinteraction<0.01, figure 2D). The metformin- to- creatinine 
clearance ratio peaked at 5.7±1.2 after 30 min of NMP 
and declined subsequently (linear regression equa-
tion=−0.014×min+5.4, R2=0.78, p<0.01; figure 2E). 
For the first 90 min, both metformin clearance and 
Figure 2 (A) Metformin clearance during the last 30 min of normothermic machine perfusion (NMP) of rat kidneys. Only 
three urine samples per pretreatment group in the 300 mg/L metformin group were available for determination of metformin 
concentration. *P<0.05. (B) Creatinine clearance during the last 30 min of NMP of rat kidneys. (C) Metformin- to- creatinine 
clearance ratio shown on a logarithmically transformed scale during the last 30 min of NMP of rat kidneys. Because only 
three urine samples per pretreatment group in the 300 mg/L metformin groups were available for the determination of the 
metformin concentration, both pretreatment groups were combined for statistical analysis. *P<0.05. **P<0.05 when combining 
pretreatment groups. (D) Metformin and creatinine clearance during NMP of metformin- treated porcine kidneys. (E) Metformin- 
to- creatinine clearance ratio of metformin- treated porcine kidneys displayed on a logarithmically transformed scale. Shown is 
a linear regression trend line with a 95% CI (dashed lines with the gray area in between). (F) Relation of metformin perfusate 
concentration with urinary elimination rate of metformin in the porcine kidney study. Displayed in red is a fit with 95% CI 
(dashed lines with the area in between) obtained from a Michaelis- Menten model. (G) Tissue metformin concentration in non- 
perfused rat kidneys, and after NMP in both the rat kidney study and porcine kidney study. *p<0.05. ***P<0.05 vs controls. 
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creatinine clearance increased over time (figure 2D). 
Metformin clearance decreased until the end of NMP 
with 48.9±19.7 mL/min/100 g (paired Student’s t- test, 
p=0.01), while creatinine clearance remained relatively 
stable (declining in total 5.0±19.7 mL/min/100 g, paired 
Student’s t- test, p=0.80). Non- linear curve fitting of the 
cross- sectional relation of metformin plasma concentra-
tion with the elimination rate using a Michaelis- Menten 
model showed substantial variation of the data (figure 2F, 
R2=0.49), but suggests saturation with a Km of 23.0 (95% 
CI 10.0 to 52.3) mg/L.
Metformin tissue level
Metformin level was measured in homogenized cortical 
kidney tissue of the contralateral kidney after nephrec-
tomy, and of experimental kidneys at the end of NMP 
in both experiments (figure 2G). The metformin tissue 
levels in non- perfused kidneys of rats that received 
metformin pretreatment were higher than the tissue 
levels found after saline pretreatment (25.4±4.7 vs 0.9±0.7 
mg/kg, p<0.01). Compared with controls receiving no 
metformin at all, metformin tissue concentration was 
increased in rats that received metformin pretreatment 
but whose kidneys were not perfused with metformin 
(3.0±0.8 vs 16.7±5.1 mg/kg, p=0.04). Metformin tissue 
level was higher in 30 mg/L perfused kidneys than 
kidneys perfused without metformin and was elevated 
even more in kidneys perfused with 300 mg/L (ANOVA, 
p<0.01). Pretreatment with metformin or saline did not 
affect metformin tissue level in the 30 mg/L (p=0.50) 
or 300 mg/L group (p=0.64). Porcine tissue metformin 
level did not differ with the 300 mg/L group in the rat 
study (p=0.93).
Tubular function and renal metabolism
Fractional sodium excretion was calculated as an indicator 
for tubular function, and a lower percentage of sodium 
being excreted corresponds with improved tubular func-
tion. A significant interaction between treatment group 
and time was found for fractional sodium excretion in the 
rat study (Pinteraction=0.04, online supplementary figure 3a). 
At 60 and 90 min of NMP, rats pretreated with metformin 
whose kidneys were subsequently perfused without the 
addition of metformin had a significantly lower fractional 
sodium excretion compared with all other treatment 
groups (online supplementary figure 3, figure 3A). In 
the porcine kidney study, fractional sodium excretion was 
not different between treatment groups (Pinteraction=0.84, 
figure 3B).
No interaction of treatment group with time was 
found for oxygen consumption in the rat study (Pinterac-
tion=0.29; online supplementary figure 3b). However, the 
total amount of oxygen consumed during the experi-
ment was significantly lower in kidneys perfused with 
300 mg/L metformin, irrespective of pretreatment, 
than controls (578±28 (controls) vs 427±18 (saline 
pretreatment, 300 mg/L metformin perfusion) vs 
405±13 (metformin pretreatment, 300 mg/L metformin 
perfusion) mLO2/100 g, p<0.01 vs controls; figure 3C). 
Oxygen consumption during NMP of porcine kidneys 
was not affected by metformin therapy (Pinteraction=0.11; 
figure 3D). Also, total oxygen consumption did not differ 
between metformin- treated porcine kidneys and controls 
(296±40 vs 382±33 mLO2/100 g, p=0.13).
The baseline lactate level was negligible in all rat kidney 
treatment groups (data not shown). Compared with all 
other treatment groups, lactate production nearly tripled 
in kidneys perfused with 300 mg/L metformin, irrespec-
tive of metformin pretreatment (figure 3E). Coupled to 
lactate production, perfusion with 300 mg/L metformin 
led to increased glucose consumption compared with 
all other experimental groups (online supplementary 
figure 4). No difference in ATP content was observed 
between the metformin and control group in the porcine 
kidney study (2.2±0.8 vs 4.9±1.5 µmol/g protein, p=0.14; 
figure 3F). Both at the start and the end of NMP of rat 
kidneys, the pH in the perfusion fluid of kidneys perfused 
with 30 mg/L metformin approximated physiological 
levels, while it was decreased in otherwise treated kidneys 
(online supplementary figure 5a, b). The pH decreased 
in metformin- treated porcine kidneys, while it remained 
relatively stable in controls, but no statistically significant 
differences were found between the treatment groups 
(Pinteraction=0.26, online supplementary figure 5c).
Gene expression of transporters
Expression of genes encoding for transporters involved 
in the transport of metformin was determined in both 
studies at the end of NMP. Gene expression of OCT-2, 
transporting metformin into the proximal tubule cell, 
in rats pretreated with metformin whose kidneys subse-
quently were perfused with 30 mg/L metformin was lower 
than gene expression in metformin pretreated rats whose 
kidneys were perfused without metformin or with 300 
mg/L metformin, respectively (figure 4A). Expression of 
OCT-1 and OCT-3 was not different between treatment 
groups. Gene expression MATE-1, encoding for a trans-
porter involved in the apical efflux of metformin, was 
not different between treatment groups in the rat study 
(figure 4B). In the porcine kidney study, gene expres-
sion of OCT-1, OCT-2 and MATE- 2K was unaffected by 
metformin treatment (figure 4C).
DISCUSSION
In this study using two different ex vivo perfusion 
models, we found that secretion accounts for a substan-
tial proportion of the total elimination of metformin. 
Metformin excretion was hampered at higher circulating 
concentrations of metformin. In contrast to our hypoth-
esis, this can mainly be explained by the saturation of 
OCTs rather than a self- inhibitory effect. Interestingly, 
rats pretreated with oral metformin whose kidneys were 
perfused without the addition of metformin had the 
highest metformin excretion, and the highest sodium 
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group did not have improved fractional sodium excretion 
compared with controls, metformin pretreatment might 
improve tubular function.23–25 Remarkably, renal func-
tion and metabolism of these ex vivo perfused kidneys 
seems to be relatively resistant to metformin concentra-
tions considered highly toxic in vivo.
Both in vivo and in vitro studies have reported that 
mitochondrial respiration and tissue oxygen consump-
tion is decreased when exposed to metformin.26–29 Such 
an effect is also seen in patients treated for metformin 
intoxication.30 In our study, oxygen consumption 
decreased in rat kidneys perfused with 300 mg/L 
metformin. Possibly, the relatively short period in which 
the kidneys were exposed to metformin might explain 
the discrepancy with previous studies assessing oxygen 
consumption. On the other hand, acute administration 
of metformin to rats was also reported not to be associ-
ated with altered oxygen demand in general and, specif-
ically, within tubules.31 Lactate production was increased 
in rat kidneys perfused with 300 mg/L metformin, indi-
cating increased anaerobic metabolism. Because lactate 
production was only affected when exposed to such a 
high metformin concentration, other tissues than the 
kidney may have a considerable role in development of 
Figure 3 (A) Fractional sodium excretion, an indicator for tubular function, during the last 30 min of normothermic machine 
perfusion (NMP) in rat kidneys and (B) during NMP of porcine kidneys. Lower fractional sodium excretion corresponds with 
improved tubular function. (C) Total oxygen consumption of rat kidneys by calculating the area under the curve of oxygen 
consumption at different time points, and (D) oxygen consumption during NMP of porcine kidneys. (E) Lactate production 
of rat kidneys during NMP. (F) ATP content measured in cortical renal tissue at the end of NMP in porcine kidneys. Data 
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metformin- induced lactic acidosis as this already occurs 
under lower metformin concentrations. Indeed, our 
group reported previously that oral administration of 
metformin alone caused a threefold increase in lactate 
production during isolated liver perfusion without addi-
tion of metformin as postconditioning agent, which is in 
line with other studies investigating the inhibitory role 
of metformin on hepatic gluconeogenesis.32–34 Beside 
inhibition of lactate metabolism, lactate production 
by porcine skeletal muscle was increased when a high 
concentration of metformin was administered locally.35 
Likewise, metformin dose- dependently caused lactate 
overproduction in human platelets.36
Beside the potential effect of metformin on its own 
elimination, OCTs are saturable at high concentra-
tions as used in our study. Previously, it was reported 
that the apparent Km ranges from 36.8 to 409.4 mg/L 
for OCT-2, from 29.3 to 100.7 mg/L for MATE-1 and 
from 135.6 to 255.7 mg/L for MATE- 2K, respectively.37 
Inhibition of MATE transporters seems to have a more 
important role in metformin transport and accumula-
tion than transporters involved in influx of metformin, 
such as OCT-2.38–40 Although we assessed elimination of 
metformin within the whole kidney rather than a cell 
line expressing a single transporter, we found a Km of 23 
mg/L which is in line with previous reports. Moreover, 
the metformin tissue level of rats whose kidneys were 
perfused with 300 mg/L metformin was approximately 
a 5- fold higher than kidneys perfused with 30 mg/L 
metformin, while a 10- fold increase in tissue level could 
be expected. Assuming that metformin tissue binding 
is low and hence unbound concentrations in tissue 
should be similar to the total concentration, saturation 
of the transporters could be a likely explanation of our 
observations.
Another explanation of our findings might be that 
metformin, being a hydrophilic base, affects the hydro-
gen- ion gradient within proximal tubules. The pH in 
the perfusion fluid during NMP of porcine kidneys 
decreased over time, which is of particular interest as 
the transport function of metformin transporters are 
compromised under acidic circumstances.7 However, 
it has been previously reported that transport by OCTs 
is only affected when the pH was below 6.9.41 Studies 
competitively inhibiting different renal transporters 
report that metformin secretion can be affected by 
several compounds.2 7 However, metformin has often 
been investigated as a substrate and, as far as we know, 
it has not been reported whether increasing metformin 
levels affect its elimination in an ex vivo isolated kidney 
perfusion model. Beside passive filtration, metformin 
and creatinine both are transported within the proximal 
tubules by the same influx transporter, OCT-2.2 There-
fore, high creatinine concentrations might competitively 
interact with tubular transport of metformin.42 However, 
a similar amount of creatinine was used in both models, 
Figure 4 (A, B) Gene expression encoding for transporters present in the proximal tubules of the rat kidneys that are involved 
in basolateral uptake (OCT-2), and apical efflux of metformin, respectively (OCT-1, MATE-1 and MATE- 2K). The exact role of 
OCT-3 in metformin transport is currently unclear. (C) Gene expression of transporters in porcine kidneys. Data are generated 
through real- time PCR using cortical kidney tissue obtained at the end of normothermic machine perfusion, and are expressed 
as mean±SEM in all panels. Primers used for this analysis are provided in online supplementary table 4. *P<0.05. MATE, 
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diminishing this effect across experimental groups. When 
exposed to extremely high metformin concentrations, 
we found that indicators of renal function were relatively 
unaffected. Long- term metformin use of patients under 
normal circumstances and during acute illness was associ-
ated with mixed, but in all cases, limited effects on renal 
function.43–49
This study has important clinical implications. 
Metformin is currently contraindicated in patients 
with significant renal dysfunction because of the risk of 
metformin accumulation and lactic acidosis.4 A better 
understanding of the pathophysiological mechanism 
causing metformin- associated lactic acidosis is paramount 
to identify patients at risk for this severe complication of 
metformin therapy. We believe our findings suggest that 
when metformin exceeds a certain threshold level, these 
transporters might get overwhelmed ultimately leading 
to metformin- induced lactic acidosis.
Surprisingly, the therapeutic concentrations of 
metformin in humans remain unknown. The US Food 
and Drug Administration reports that 5 mg/L is the 
maximal level measured during controlled clinical trials 
which served as basis of approval for metformin, and 
thus this level is often considered as toxic threshold.50 
In rats pretreated with metformin whose kidneys were 
not perfused metformin and during the first 90 min 
of normothermic perfusion of porcine kidneys, the 
metformin concentration in plasma remained below this 
level. Importantly, the metformin concentrations used 
in the other experimental groups in the rat study, and 
during the second half of NMP of porcine kidneys should 
be considered as massive doses which are associated with 
severe toxicity in both animals and humans when admin-
istered systemically.30 36
This study has some limitations which have to be 
pointed out. To increase the robustness of our findings, 
we applied two different study designs using parallel 
pretreated groups with distinct doses of metformin in the 
rat study and administration of increasing amounts of 
metformin during NMP in the porcine study. However, the 
concentration of metformin in perfusion fluid increased 
quickly, which might have affected our ability to find an 
effect as we did not measure metformin clearance contin-
uously. We investigated the effects of metformin on its 
elimination at a functional level, using clinically relevant 
biomarkers that unfortunately could not provide more 
in- depth answers. We were unable to determine alter-
ations in mitochondrial respiration, as that would require 
freshly isolated mitochondria. Furthermore, the results 
of the rat study were largely dependent on the compar-
ison of rats pretreated with metformin whose kidneys 
subsequently were not perfused with metformin on the 
one hand with the other experimental groups on the 
other hand. In contrast, we only assessed changes over 
time of metformin- treated kidneys in the porcine study. 
Probably inherent to NMP models in general,14–16 18 
substantial variability is apparent for all outcome param-
eters including metformin clearance. Because we found 
similar dose- dependent results across both models, we 
do not believe that variability in renal function hampers 
interpretation of our results.
In conclusion, metformin clearance was considerably 
higher than creatinine clearance, indicating secretion of 
metformin during ex vivo NMP of both rat and porcine 
kidneys. Metformin clearance was reduced under 
increasing concentrations of plasma metformin, whereas 
creatinine clearance and fractional sodium excretion 
remained relatively unaffected. This can be explained 
by the saturation of OCTs rather than a self- inhibitory 
effect, but this observation should be considered in light 
of short- term exposure to high levels of metformin in our 
study. As patients with metformin- induced lactic acidosis 
presumably are exposed to toxic metformin concentra-
tions for a longer period, it remains unknown whether a 
self- inhibitory effect contributes to metformin accumula-
tion in humans.
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